<p>Ultragenyx Pharmaceutical（納斯達克代碼：RARE - 獲取免費報告）在週日發佈給投資者的報告中，被華爾街 Zen 從 “賣出” 評級上調至 “持有” 評級。</p>
<ul>
<li>分析師表示這兩家中型生物科技公司具有兩倍的潛力</li>
</ul>
<p>其他幾位股票研究分析師也最近對該公司發表了看法。Truist Financial 在 3 月 25 日的報告中將 Ultragenyx Pharmaceutical 的評級上調至 “強力買入”。Guggenheim 在 1 月 5 日的報告中將 Ultragenyx Pharmaceutical 的目標價從 64.00 美元下調至 52.00 美元，並給予該公司 “買入” 評級。摩根大通在 3 月 12 日的報告中將 Ultragenyx Pharmaceutical 的目標價從 120.00 美元下調至 74.00 美元，並給予該公司 “增持” 評級。高盛在 3 月 24 日的報告中將 Ultragenyx Pharmaceutical 的評級從 “買入” 下調至 “中性”，並將其股票目標價從 61.00 美元下調至 25.00 美元。最後，Wedbush 在 2 月 17 日的報告中重申了 “中性” 評級，並對 Ultragenyx Pharmaceutical 的股票設定了 25.00 美元的目標價。一位股票研究分析師給予該股票 “強力買入” 評級，十四位給予 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價為 60.76 美元。</p>
<p><strong>查看我們關於 Ultragenyx Pharmaceutical 的最新股票報告</strong></p>
<h2>Ultragenyx Pharmaceutical 股票表現</h2>
<p>納斯達克 RARE 週五開盤價為 24.77 美元。該股票的 50 日移動平均價格為 22.50 美元，200 日移動平均價格為 26.99 美元。Ultragenyx Pharmaceutical 的年低為 18.29 美元，年高為 42.37 美元。該公司的市值為 24.4 億美元，市盈率為-4.24，貝塔值為 0.38。</p>
<p>Ultragenyx Pharmaceutical（納斯達克代碼：RARE - 獲取免費報告）最近於 2 月 12 日發佈了其財報。這家生物製藥公司報告每股收益（EPS）為-1.29 美元，低於市場共識預期的-1.20 美元，差距為 0.09 美元。Ultragenyx Pharmaceutical 的淨利潤率為-85.54%，股本回報率為-1,024.42%。該公司在本季度的收入為 2.0728 億美元，而分析師預期為 1.9960 億美元。去年同期，該公司每股收益為-1.39 美元。Ultragenyx Pharmaceutical 本季度的收入同比增長 25.5%。整體來看，股票分析師預測 Ultragenyx Pharmaceutical 在當前財政年度的每股收益為-4.49 美元。</p>
<h2>內部人士下注</h2>
<p>在其他 Ultragenyx Pharmaceutical 的新聞中，執行副總裁 Eric Crombez 於 3 月 2 日的交易中出售了 7,029 股該公司的股票。該股票以平均價格 22.80 美元出售，總價值為 160,261.20 美元。出售完成後，該執行副總裁持有 76,301 股公司股票，價值約為 1,739,662.80 美元。這筆交易代表其持股減少了 8.44%。該出售在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。此外，首席執行官 Emil D. Kakkis 於 3 月 2 日的交易中出售了 54,404 股 Ultragenyx Pharmaceutical 的股票。該股票以平均價格 22.80 美元出售，總價值為 1,240,411.20 美元。出售後，首席執行官直接持有 658,994 股公司股票，價值為 15,025,063.20 美元。這筆交易代表其持股減少了 7.63%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士已出售 109,556 股公司股票，價值為 2,490,138 美元。當前 5.20% 的股票由公司內部人士持有。</p>
<h2>Ultragenyx Pharmaceutical 的機構交易</h2>
<p>機構投資者和對沖基金最近買賣了該公司的股票。Aquatic Capital Management LLC 在第三季度將其在 Ultragenyx Pharmaceutical 的股份增加了 79.1%。Aquatic Capital Management LLC 目前持有 191,458 股該生物製藥公司的股票，價值為 5,759,000 美元，此前在該期間內又收購了 84,559 股。SG Americas Securities LLC 在第三季度收購了 Ultragenyx Pharmaceutical 的新股份，價值約為 3,773,000 美元。Aberdeen Group plc 在第三季度將其在 Ultragenyx Pharmaceutical 的股份增加了 94.3%。Aberdeen Group plc 目前持有 973,656 股該生物製藥公司的股票，價值為 29,288,000 美元，此前在該期間內又收購了 472,600 股。WCM Investment Management LLC 在第三季度將其在 Ultragenyx Pharmaceutical 的股份增加了 36.9%。WCM Investment Management LLC 目前持有 288,109 股該生物製藥公司的股票，價值為 8,747,000 美元，此前在該期間內又收購了 77,640 股。最後，Thornburg Investment Management Inc.在第三季度收購了 Ultragenyx Pharmaceutical 的新股份，價值約為 2,083,000 美元。當前 97.67% 的股票由機構投資者和對沖基金持有。</p>
<h2>Ultragenyx Pharmaceutical 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Ultragenyx Pharmaceutical Inc 是一家生物製藥公司，專注於開發和商業化針對罕見和超罕見遺傳疾病的療法。自 2010 年成立以來，總部位於加利福尼亞州諾瓦託，該公司在蛋白質替代療法、小分子和基因療法方面積累了專業知識，以應對高度未滿足的醫療需求。Ultragenyx 採用精準醫學模型，利用內部研究和戰略合作來推進其產品管道，從發現到監管批准。</p>
<p>該公司的商業產品組合包括用於 X 連鎖低磷血癥的 Crysvita（burosumab-tmyl）、用於粘多糖貯積症 VII 的 Mepsevii（vestronidase alfa-vjbk）以及用於長鏈脂肪酸氧化障礙的 Dojolvi（triheptanoin）。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們認為比 Ultragenyx Pharmaceutical 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Ultragenyx Pharmaceutical 嗎？</h2>
<p>在考慮 Ultragenyx Pharmaceutical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Ultragenyx Pharmaceutical 並不在名單上。</p>
<p>雖然 Ultragenyx Pharmaceutical 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Ultragenyx制藥

標普全球醫療股指數 ETF - iShares

美國制藥 ETF - iShares

<p>華爾街禪將 Ultragenyx 製藥（NASDAQ:RARE）的評級從 “賣出” 上調至 “持有”。其他分析師的看法不一，Truist Financial 給予 “強力買入” 評級，而高盛則將其下調至 “中性”。該股票開盤價為 24.77 美元，市值為 24.4 億美元。最近的財報顯示每股虧損為（1.29 美元），但收入同比增長了 25.5%。內部人士最近出售了股份，而機構投資者則增加了對公司的持股</p>

<p>Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) was upgraded by Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a note issued to investors on Sunday.</p>
<div class="lb-trans"><p>Ultragenyx Pharmaceutical（納斯達克代碼：RARE - 獲取免費報告）在週日發佈給投資者的報告中，被華爾街 Zen 從 “賣出” 評級上調至 “持有” 評級。</p>
</div><ul>
<li>Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師表示這兩家中型生物科技公司具有兩倍的潛力</li>
</ul>
</div><p>Several other equities research analysts also recently weighed in on the company. Truist Financial raised Ultragenyx Pharmaceutical to a &#34;strong-buy&#34; rating in a report on Wednesday, March 25th. Guggenheim lowered their price target on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a &#34;buy&#34; rating for the company in a report on Monday, January 5th. JPMorgan Chase &amp; Co. lowered their price target on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an &#34;overweight&#34; rating for the company in a report on Thursday, March 12th. The Goldman Sachs Group downgraded Ultragenyx Pharmaceutical from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and lowered their price target for the stock from $61.00 to $25.00 in a report on Tuesday, March 24th. Finally, Wedbush reissued a &#34;neutral&#34; rating and issued a $25.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $60.76.</p>
<div class="lb-trans"><p>其他幾位股票研究分析師也最近對該公司發表了看法。Truist Financial 在 3 月 25 日的報告中將 Ultragenyx Pharmaceutical 的評級上調至 “強力買入”。Guggenheim 在 1 月 5 日的報告中將 Ultragenyx Pharmaceutical 的目標價從 64.00 美元下調至 52.00 美元，並給予該公司 “買入” 評級。摩根大通在 3 月 12 日的報告中將 Ultragenyx Pharmaceutical 的目標價從 120.00 美元下調至 74.00 美元，並給予該公司 “增持” 評級。高盛在 3 月 24 日的報告中將 Ultragenyx Pharmaceutical 的評級從 “買入” 下調至 “中性”，並將其股票目標價從 61.00 美元下調至 25.00 美元。最後，Wedbush 在 2 月 17 日的報告中重申了 “中性” 評級，並對 Ultragenyx Pharmaceutical 的股票設定了 25.00 美元的目標價。一位股票研究分析師給予該股票 “強力買入” 評級，十四位給予 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價為 60.76 美元。</p>
</div><p><strong>View Our Latest Stock Report on Ultragenyx Pharmaceutical</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Ultragenyx Pharmaceutical 的最新股票報告</strong></p>
</div><h2>Ultragenyx Pharmaceutical Stock Performance</h2>
<div class="lb-trans"><h2>Ultragenyx Pharmaceutical 股票表現</h2>
</div><p>NASDAQ RARE opened at $24.77 on Friday. The stock has a 50 day moving average price of $22.50 and a 200-day moving average price of $26.99. Ultragenyx Pharmaceutical has a one year low of $18.29 and a one year high of $42.37. The company has a market capitalization of $2.44 billion, a P/E ratio of -4.24 and a beta of 0.38.</p>
<div class="lb-trans"><p>納斯達克 RARE 週五開盤價為 24.77 美元。該股票的 50 日移動平均價格為 22.50 美元，200 日移動平均價格為 26.99 美元。Ultragenyx Pharmaceutical 的年低為 18.29 美元，年高為 42.37 美元。該公司的市值為 24.4 億美元，市盈率為-4.24，貝塔值為 0.38。</p>
</div><p>Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The company had revenue of $207.28 million during the quarter, compared to analysts' expectations of $199.60 million. During the same quarter last year, the firm earned ($1.39) EPS. Ultragenyx Pharmaceutical's revenue for the quarter was up 25.5% on a year-over-year basis. As a group, equities analysts predict that Ultragenyx Pharmaceutical will post -4.49 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Ultragenyx Pharmaceutical（納斯達克代碼：RARE - 獲取免費報告）最近於 2 月 12 日發佈了其財報。這家生物製藥公司報告每股收益（EPS）為-1.29 美元，低於市場共識預期的-1.20 美元，差距為 0.09 美元。Ultragenyx Pharmaceutical 的淨利潤率為-85.54%，股本回報率為-1,024.42%。該公司在本季度的收入為 2.0728 億美元，而分析師預期為 1.9960 億美元。去年同期，該公司每股收益為-1.39 美元。Ultragenyx Pharmaceutical 本季度的收入同比增長 25.5%。整體來看，股票分析師預測 Ultragenyx Pharmaceutical 在當前財政年度的每股收益為-4.49 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other Ultragenyx Pharmaceutical news, EVP Eric Crombez sold 7,029 shares of the firm's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $160,261.20. Following the completion of the sale, the executive vice president owned 76,301 shares of the company's stock, valued at approximately $1,739,662.80. This trade represents a 8.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CEO Emil D. Kakkis sold 54,404 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the sale, the chief executive officer directly owned 658,994 shares of the company's stock, valued at $15,025,063.20. This trade represents a 7.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 109,556 shares of company stock valued at $2,490,138. 5.20% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Ultragenyx Pharmaceutical 的新聞中，執行副總裁 Eric Crombez 於 3 月 2 日的交易中出售了 7,029 股該公司的股票。該股票以平均價格 22.80 美元出售，總價值為 160,261.20 美元。出售完成後，該執行副總裁持有 76,301 股公司股票，價值約為 1,739,662.80 美元。這筆交易代表其持股減少了 8.44%。該出售在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。此外，首席執行官 Emil D. Kakkis 於 3 月 2 日的交易中出售了 54,404 股 Ultragenyx Pharmaceutical 的股票。該股票以平均價格 22.80 美元出售，總價值為 1,240,411.20 美元。出售後，首席執行官直接持有 658,994 股公司股票，價值為 15,025,063.20 美元。這筆交易代表其持股減少了 7.63%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士已出售 109,556 股公司股票，價值為 2,490,138 美元。當前 5.20% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Trading of Ultragenyx Pharmaceutical</h2>
<div class="lb-trans"><h2>Ultragenyx Pharmaceutical 的機構交易</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the business. Aquatic Capital Management LLC lifted its stake in Ultragenyx Pharmaceutical by 79.1% during the 3rd quarter. Aquatic Capital Management LLC now owns 191,458 shares of the biopharmaceutical company's stock valued at $5,759,000 after acquiring an additional 84,559 shares during the period. SG Americas Securities LLC acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $3,773,000. Aberdeen Group plc lifted its stake in Ultragenyx Pharmaceutical by 94.3% during the 3rd quarter. Aberdeen Group plc now owns 973,656 shares of the biopharmaceutical company's stock valued at $29,288,000 after acquiring an additional 472,600 shares during the period. WCM Investment Management LLC lifted its stake in Ultragenyx Pharmaceutical by 36.9% during the 3rd quarter. WCM Investment Management LLC now owns 288,109 shares of the biopharmaceutical company's stock valued at $8,747,000 after acquiring an additional 77,640 shares during the period. Finally, Thornburg Investment Management Inc. acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $2,083,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近買賣了該公司的股票。Aquatic Capital Management LLC 在第三季度將其在 Ultragenyx Pharmaceutical 的股份增加了 79.1%。Aquatic Capital Management LLC 目前持有 191,458 股該生物製藥公司的股票，價值為 5,759,000 美元，此前在該期間內又收購了 84,559 股。SG Americas Securities LLC 在第三季度收購了 Ultragenyx Pharmaceutical 的新股份，價值約為 3,773,000 美元。Aberdeen Group plc 在第三季度將其在 Ultragenyx Pharmaceutical 的股份增加了 94.3%。Aberdeen Group plc 目前持有 973,656 股該生物製藥公司的股票，價值為 29,288,000 美元，此前在該期間內又收購了 472,600 股。WCM Investment Management LLC 在第三季度將其在 Ultragenyx Pharmaceutical 的股份增加了 36.9%。WCM Investment Management LLC 目前持有 288,109 股該生物製藥公司的股票，價值為 8,747,000 美元，此前在該期間內又收購了 77,640 股。最後，Thornburg Investment Management Inc.在第三季度收購了 Ultragenyx Pharmaceutical 的新股份，價值約為 2,083,000 美元。當前 97.67% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Ultragenyx Pharmaceutical Company Profile</h2>
<div class="lb-trans"><h2>Ultragenyx Pharmaceutical 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.</p>
<div class="lb-trans"><p>Ultragenyx Pharmaceutical Inc 是一家生物製藥公司，專注於開發和商業化針對罕見和超罕見遺傳疾病的療法。自 2010 年成立以來，總部位於加利福尼亞州諾瓦託，該公司在蛋白質替代療法、小分子和基因療法方面積累了專業知識，以應對高度未滿足的醫療需求。Ultragenyx 採用精準醫學模型，利用內部研究和戰略合作來推進其產品管道，從發現到監管批准。</p>
</div><p>The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.</p>
<div class="lb-trans"><p>該公司的商業產品組合包括用於 X 連鎖低磷血癥的 Crysvita（burosumab-tmyl）、用於粘多糖貯積症 VII 的 Mepsevii（vestronidase alfa-vjbk）以及用於長鏈脂肪酸氧化障礙的 Dojolvi（triheptanoin）。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Ultragenyx Pharmaceutical</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Ultragenyx Pharmaceutical 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=RARE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ultragenyx Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Ultragenyx Pharmaceutical 嗎？</h2>
</div><p>Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Ultragenyx Pharmaceutical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Ultragenyx Pharmaceutical 並不在名單上。</p>
</div><p>While Ultragenyx Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Ultragenyx Pharmaceutical 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Ultragenyx 製藥（NASDAQ:RARE）在 Wall Street Zen 被上調至持有評級